NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session NewAmsterdam Pharma (Nasdaq: NAMS) will present three digital posters at the American College of Cardiology Annual Scientific Session (ACC.26) in New Orleans, March 28-30, 2026.The presentations cover obicetrapib kidney outcomes from BROADWAY, a pooled Phase III safety analysis, and LDL particle–CVD risk relationships, with presenters from company leadership and collaborators.

#NAMS #NAMSW NewAmsterdam Pharma Announces Three Presentations at the 2026 American College of Cardiology Annual Scientific Session

www.stocktitan.net/news/NAMS/new-amsterdam-...

NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities -- First patient enrolled in RUBENS Phase 3 trial of obicetrapib and obicetrapib/ezetimibe fixed dose

#NAMS #NAMSW NewAmsterdam Pharma Highlights 2025 Achievements and Outlines 2026 Strategic Priorities

www.stocktitan.net/news/NAMS/new-amsterdam-...

NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results NewAmsterdam Pharma (Nasdaq: NAMS) reported third-quarter 2025 results and a corporate update focused on obicetrapib development and regulatory progress.Key points: EMA accepted MAAs for obicetrapib 10 mg monotherapy and a 10/10 mg obicetrapib/ezetimibe FDC; pooled BROADWAY and BROOKLYN analyses were published in JACC and a BROADWAY Alzheimer’s substudy in Journal of Prevention of Alzheimer's Disease. Cash, cash equivalents and marketable securities were $756.0 million at September 30, 2025; Q3 revenue was $0.3M and net loss was $72.0M.

#NAMS #NAMSW NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results

www.stocktitan.net/news/NAMS/new-amsterdam-...

NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib NewAmsterdam Pharma (NASDAQ:NAMS) announced that the European Medicines Agency (EMA) has validated Marketing Authorization Applications for obicetrapib, both as a 10mg monotherapy and as a fixed-dose combination with ezetimibe. The applications, submitted by partner Menarini, target adults with primary hypercholesterolemia or mixed dyslipidemia.The submissions are supported by three pivotal Phase 3 trials: BROADWAY, BROOKLYN, and TANDEM, which demonstrated LDL-C reductions of 35-40% for obicetrapib monotherapy and approximately 50% when combined with ezetimibe versus placebo. Under the partnership agreement, NewAmsterdam is eligible for up to €833 million in milestone payments and tiered double-digit royalties ranging from low double-digits to mid-twenties on net sales in Menarini's territory.

#NAMS #NAMSW NewAmsterdam Announces Acceptance of Marketing Authorization Applications for Review by European Medicine Agency for Obicetrapib

www.stocktitan.net/news/NAMS/new-amsterdam-...

NewAmsterdam Reports Breakthrough: Cholesterol Drug Shows Promise in Alzheimer's Disease While Revenue Jumps 730% Clinical trial reveals 20.5% reduction in Alzheimer's biomarkers, while Q2 revenue surges to $19.1M. European marketing application advances. See full results.

#NAMS #NAMSW NewAmsterdam Pharma Provides Corporate Update and Reports Second Quarter Financial Results

www.stocktitan.net/news/NAMS/new-amsterdam-...

NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025 NewAmsterdam Pharma (NASDAQ: NAMS) has announced positive data from its BROADWAY trial, demonstrating significant reductions in Alzheimer's disease biomarkers. The trial showed that obicetrapib significantly reduced plasma p-tau217 levels, a key Alzheimer's biomarker, in both the full analysis set (p=0.0019) and ApoE4 carriers (p=0.0215).Most notably, in APOE4/E4 carriers, who face the highest risk for Alzheimer's, obicetrapib reduced p-tau217 levels by 20.5% over 12 months compared to placebo (p=0.010). The study included 1,515 patients, with 367 being ApoE4 carriers. Additional biomarkers including NFL, GFAP, p-tau181, and Aβ42/40 ratio also showed favorable trends, particularly in carriers of two E4 proteins.These results complement obicetrapib's established cardiometabolic benefits, suggesting potential as a dual-action therapy for both cardiovascular and neurodegenerative conditions.

#NAMS #NAMSW NewAmsterdam Pharma Presents Positive Data from BROADWAY Trial Demonstrating Statistically Significant Reductions in Key Alzheimer’s Disease Biomarkers at AAIC 2025

www.stocktitan.net/news/NAMS/new-amsterdam-...

NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial NewAmsterdam Pharma (NAMS) announced positive topline data from their Phase 3 BROADWAY trial's Alzheimer's Disease sub-study for obicetrapib. The study demonstrated statistically significant reductions in Alzheimer's disease biomarkers, particularly p-tau217, in both the general population (p

#NAMS #NAMSW NewAmsterdam Pharma Announces Positive Topline Alzheimer’s Disease Data from BROADWAY Clinical Trial

www.stocktitan.net/news/NAMS/new-amsterdam-...

NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results NewAmsterdam Pharma (NAMS) reported Q1 2025 financial results and corporate updates. The company ended Q1 with $808.5 million in cash and equivalents, down from $834.2 million in Q4 2024. Q1 revenue was $3.0 million, up from $1.4 million year-over-year, while net loss improved to $39.5 million from $93.8 million. R&D expenses increased to $44.8 million, and SG&A expenses rose to $27.2 million. The company's lead drug candidate obicetrapib, an oral CETP inhibitor for LDL-C reduction, saw positive developments with data presented at EAS and published in prestigious journals. Key ongoing trials include the PREVAIL Phase 3 CVOT with over 9,500 patients, VINCENT Phase 2 for Lp(a), and REMBRANDT Phase 3 for coronary plaque evaluation. Partner Menarini plans EMA submission in 2H25.

#NAMS #NAMSW NewAmsterdam Pharma Provides Corporate Update and Reports First Quarter Financial Results

www.stocktitan.net/news/NAMS/new-amsterdam-...

Can NewAmsterdam's Obicetrapib Reshape Cardiovascular Treatment? Phase 3 Results Show 49% LDL-C Reduction Obicetrapib achieved 33-49% LDL-C reduction across three Phase 3 trials. Company reports $834.2M cash position with revenue up 223% to $45.6M.

#NAMS #NAMSW NewAmsterdam Pharma Reports Full Year 2024 Financial Results and Provides Corporate Update

www.stocktitan.net/news/NAMS/new-amsterdam-...

NewAmsterdam's Cholesterol Drug Achieves Major Breakthroughs: 33% LDL-C Drop in Phase 3 Trials NewAmsterdam Pharma reports breakthrough results for obicetrapib across three Phase 3 trials, showing up to 49% LDL-C reduction. Strong $835M cash position fuels path to commercialization.

#NAMS #NAMSW NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities

www.stocktitan.net/news/NAMS/new-amsterdam-...

NewAmsterdam Pharma Launches Massive $416.5M Public Offering with Upsized Share Sale NewAmsterdam Pharma prices upsized offering of 17M shares and warrants at $24.50, backed by major investment banks. Significant capital raise strengthens financial position.

#NAMS #NAMSW NewAmsterdam Pharma Announces Pricing of Upsized $416.5 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

#offering #StockMarket #investing

www.stocktitan.net/news/NAMS/new-amsterdam-...

NewAmsterdam Pharma Launches Massive $300M Public Offering with Pre-Funded Warrants NewAmsterdam Pharma announces substantial capital raise through public offering of shares and warrants, backed by major Wall Street firms. Includes $45M additional option.

#NAMS #NAMSW NewAmsterdam Pharma Announces Commencement of $300 Million Public Offering of Ordinary Shares and Pre-Funded Warrants

#offering #investing #StockMarket

www.stocktitan.net/news/NAMS/new-amsterdam-...

NEWS: ( NASDAQ: #NAMSW ) NewAmsterdam Pharma Announces Positive Topline Data from Pivotal Phase 3 BROADWAY Clinical Trial Evaluating Obicetrapib in Patients with Atherosclerotic Cardiovascular Disease and/or Heterozygous Familial Hypercholesterolemia

#StockMarket #News

JUST IN: ( NASDAQ: #NAMSW ) NewAmsterdam Pharma Provides Corporate Update and Reports Third Quarter Financial Results

#StockMarket #News